Neuraxis enters $3.3 million at-the-market equity offering agreement

Neuraxis, Inc. (NYSE American:NRXS), a small-cap healthcare company with a market capitalization of $25 million, announced Tuesday that it entered into an At The Market Offering Agreement with Craig-Hallum Capital Group LLC, enabling the company to offer and sell up to $3.3 million of its common stock from time to time. The agreement was executed on August 29, 2025. According to InvestingPro data, the company’s stock has shown significant volatility, currently trading at $2.54.

According to a statement in a press release based on the company’s filing with the Securities and Exchange Commission, Neuraxis may sell shares at its discretion through Craig-Hallum acting as sales agent. Sales will be made under Neuraxis’s effective registration statement on Form S-3, filed with the SEC and declared effective earlier this year. The prospectus supplement related to this offering was filed on August 29.

Under the terms of the agreement, Craig-Hallum will use commercially reasonable efforts to sell shares according to instructions from Neuraxis, including any price, time, or size parameters the company may set. The company will pay Craig-Hallum a commission of 3% of the gross proceeds from stock sales. Neuraxis will also reimburse up to $50,000 in legal counsel fees for the sales agent, with additional disbursements of up to $5,000 for each due diligence update session.

The agreement also provides Craig-Hallum with customary indemnification rights. The company attached a legal opinion from Lucosky Brookman LLP related to the shares as part of the SEC filing.

The filing notes that this report does not constitute an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction where such an offer or sale would be unlawful.

All information is based on statements in a press release and the company’s Form 8-K filed with the SEC.

In other recent news, Neuraxis Inc. reported a significant 46% increase in revenue for the second quarter of 2025 compared to the previous year. This growth highlights the company’s strategic efforts in expanding its product line and increasing market penetration. Despite experiencing an operating loss, Neuraxis remains optimistic about its future, citing new FDA indications and strategic initiatives as drivers for growth. These developments are crucial for investors as they consider the company’s potential trajectory. The positive revenue results suggest that Neuraxis’s strategies might be yielding favorable outcomes. However, the operating loss indicates challenges that the company continues to face. Investors will be keenly watching how Neuraxis navigates these challenges while pursuing its growth initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.